1 reports of this reaction
4.2% of all BERBERIS VULGARIS ROOT BARK reports
#14 most reported adverse reaction
MALIGNANT NEOPLASM PROGRESSION is the #14 most commonly reported adverse reaction for BERBERIS VULGARIS ROOT BARK, manufactured by BM Private Limited. There are 1 FDA adverse event reports linking BERBERIS VULGARIS ROOT BARK to MALIGNANT NEOPLASM PROGRESSION. This represents approximately 4.2% of all 24 adverse event reports for this drug.
Patients taking BERBERIS VULGARIS ROOT BARK who experience malignant neoplasm progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MALIGNANT NEOPLASM PROGRESSION is moderately reported among BERBERIS VULGARIS ROOT BARK users, representing a notable but not dominant share of adverse events.
In addition to malignant neoplasm progression, the following adverse reactions have been reported for BERBERIS VULGARIS ROOT BARK:
The following drugs have also been linked to malignant neoplasm progression in FDA adverse event reports:
MALIGNANT NEOPLASM PROGRESSION has been reported as an adverse event in 1 FDA reports for BERBERIS VULGARIS ROOT BARK. This does not prove causation, but indicates an association observed in post-market surveillance data.
MALIGNANT NEOPLASM PROGRESSION accounts for approximately 4.2% of all adverse event reports for BERBERIS VULGARIS ROOT BARK, making it a notable side effect.
If you experience malignant neoplasm progression while taking BERBERIS VULGARIS ROOT BARK, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.